📊 PROF Key Takeaways
Is Profound Medical Corp. (PROF) a Good Investment?
Pre-commercial medical device company with strong 51% YoY revenue growth and healthy 72% gross margins, but significant operating losses and negative free cash flow indicate the company is years from profitability. With $50.3M cash providing ~5.8 years of runway at current burn rates, execution risk on commercialization is elevated despite favorable balance sheet positioning.
Profound Medical Corp. Key Strengths (PROF)
- Strong revenue growth of 50.7% YoY demonstrates market traction and adoption
- Excellent gross margins of 71.8% indicate strong product-market fit and pricing power
- Fortress balance sheet with $50.3M cash, low 0.08x debt-to-equity, and 6.56x current ratio provides substantial financial runway
PROF Stock Risks: Profound Medical Corp. Investment Risks
- Severe operating losses (-150% margin) and negative free cash flow (-$8.6M annually) indicate unsustainable cash burn at operating level
- Cash runway of approximately 5-6 years at current burn rate creates hard execution deadline for reaching profitability
- Medical device sector faces prolonged commercialization cycles and regulatory constraints that could extend losses beyond available capital
Key Metrics to Watch
- Operating cash flow trajectory - must trend toward positive to signal business sustainability
- Revenue growth repeatability - confirm 50% growth rate is sustainable and not one-time event
- Operating margin improvement - monitor if gross profit growth translates to operating leverage and cost discipline
Profound Medical Corp. (PROF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.56x current ratio provides a solid financial cushion.
PROF Profit Margin, ROE & Profitability Analysis
PROF vs Healthcare Sector: How Profound Medical Corp. Compares
How Profound Medical Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Profound Medical Corp. Stock Overvalued? PROF Valuation Analysis 2026
Based on fundamental analysis, Profound Medical Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Profound Medical Corp. Balance Sheet: PROF Debt, Cash & Liquidity
PROF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Profound Medical Corp.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $1.12 reflects profitable operations.
PROF Revenue Growth, EPS Growth & YoY Performance
PROF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5M | -$6.6M | $0.26 |
| Q2 2025 | $2.0M | -$6.6M | $0.28 |
| Q1 2025 | $1.2M | -$6.6M | $0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Profound Medical Corp. Dividends, Buybacks & Capital Allocation
PROF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Profound Medical Corp. (CIK: 0001628808)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PROF
What is the AI rating for PROF?
Profound Medical Corp. (PROF) has an AI grade of B with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PROF's key strengths?
Claude: Strong revenue growth of 50.7% YoY demonstrates market traction and adoption. Excellent gross margins of 71.8% indicate strong product-market fit and pricing power.
What are the risks of investing in PROF?
Claude: Severe operating losses (-150% margin) and negative free cash flow (-$8.6M annually) indicate unsustainable cash burn at operating level. Cash runway of approximately 5-6 years at current burn rate creates hard execution deadline for reaching profitability.
What is PROF's revenue and growth?
Profound Medical Corp. reported revenue of $5.3M.
Does PROF pay dividends?
Profound Medical Corp. does not currently pay dividends.
Where can I find PROF SEC filings?
Official SEC filings for Profound Medical Corp. (CIK: 0001628808) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PROF's EPS?
Profound Medical Corp. has a diluted EPS of $0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PROF's fundamental grade?
Based on our AI fundamental analysis in May 2026, Profound Medical Corp. has a B grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PROF stock overvalued or undervalued?
Valuation metrics for PROF: ROE of -11.9% (sector avg: 15%), net margin of -132.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PROF's AI grade for 2026?
Our dual AI analysis gives Profound Medical Corp. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PROF's free cash flow?
Profound Medical Corp.'s operating cash flow is $-8.6M, with capital expenditures of $176.0K. FCF margin is -164.1%.
How does PROF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -132.2% (avg: 12%), ROE -11.9% (avg: 15%), current ratio 6.56 (avg: 2).